# Pablo Legorreta

> Pablo Legorreta is the founder, chief executive officer and chairman of Royalty Pharma. After studying industrial engineering in Mexico City and working at Lazard in Paris and New York, he established the business in 1996, building a company that acquires royalty rights and supplies capital to life sciences organizations. Royalty Pharma listed on Nasdaq in 2020 and acquired its external manager in 2025.

- **Role:** Founder, Chief Executive Officer and Chairman at Royalty Pharma
- **Organizations:** Royalty Pharma, Pharmakon Advisors, ProKidney, New York Academy of Sciences, Rockefeller University, Park Avenue Armory
- **Nationality:** Mexican-American
- **Education:** Industrial engineering, Universidad Iberoamericana, Mexico City
- **Known for:** Built Royalty Pharma from its 1996 founding into a Nasdaq-listed royalty investment company., Led Royalty Pharma through its 2020 initial public offering., Co-founded Pharmakon Advisors.

## Career timeline

- **Before 1996** — Worked in investment banking at Lazard Frères in Paris and New York.
- **1993-1994** — Developed two royalty acquisition vehicles before founding Royalty Pharma.
- **1996** — Founded Royalty Pharma with Rory Riggs; raised $60 million.
- **2003** — Royalty Pharma raised $190 million in debt.
- **2004** — Royalty Pharma adopted an evergreen business structure.
- **2009** — Co-founded Pharmakon Advisors.
- **2020** — Royalty Pharma began Nasdaq trading on June 16 as RPRX after pricing approximately $2.18 billion of shares.
- **2024** — Equity interests in the external manager were granted to 35 team members.
- **2025** — Royalty Pharma completed the RP Management acquisition on May 16.

## Achievements

- Built Royalty Pharma from its 1996 founding into a Nasdaq-listed royalty investment company.
- Led Royalty Pharma through its 2020 initial public offering.
- Co-founded Pharmakon Advisors.
- Led the 2025 internalization of Royalty Pharma’s external manager.

## Latest updates

- **2026-08** — Royalty Pharma reported second-quarter Portfolio Receipts of $773 million and Royalty Receipts of $768 million; full-year Portfolio Receipts guidance increased to $3.4 billion-$3.5 billion.
- **2025-05** — Royalty Pharma completed the RP Management acquisition, supported by 99.9% of votes cast.

## Links

- Website: https://www.royaltypharma.com/our-firm/meet-the-team/pablo-legorreta/
- LinkedIn: https://www.linkedin.com/in/pablo-legorreta-68b75849

---

Profile page: https://yespress.io/pablo-legorreta
Published by YesPress — https://yespress.io
Last updated: 2026-10-23